Geneva: The World Health Organization (WHO) has issued a global safety alert highlighting the risk of non-arteritic anterior ...

Rybelsus interacts with food, supplements, and other drugs. An interaction can occur because one substance causes another substance to have a different effect than expected. Interactions can also ...

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also stave off dementia?

Rybelsus is a GLP-1 receptor agonist drug that's prescribed to treat type 2 diabetes in adults. Learn the key facts you should know about this medication before taking it.

The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by r ...

For the first time, 40-year-old Manmeet Bindra feels motivated to exercise and has set up a home gym, cleaned up her diet and ...

Novo Nordisk’s , opens new tab diabetes medicine Rybelsus, an oral form of the GLP-1 drug semaglutide, provides similar cardiovascular benefits as the injectable forms of the drug, researchers ...

Spending also varied by brand and type of product. Spending on Ozempic increased from $400 million to $26.4 billion from 2018 to 2023. And by 2023, semaglutide (Ozempic, Rybelsus and Wegovy) and ...

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...

Rybelsus met its primary endpoint, reducing the risk of MACE by 14%, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke compared to placebo. Additionally, a secondary ...

Global payments processors Visa and Mastercard's default multilateral interchange fees which are charged to retailers ...

More than a dozen lawsuits filed in New York and New Jersey claim that weight-loss drugs like Wegovy and Ozempic caused ...